Net cash used in operations was approximately $10.6 million in 2022, compared to $10.4 million in 2021. The Company ended the year with cash and cash equivalents totaling $7.4 million, providing runway into the third quarter of 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCDA:
- BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
- Biocardia (BCDA) Q4 Earnings Cheat Sheet
- BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial
- BioCardia and CellProthera extend partnership agreement
- BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
